Ascentage Pharma’s US Shares Climb

Ascentage raises $126m in first biotech IPO of 2025
Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.
Ascentage Pharma CEO Dr. Yang on IPO
Dr. Dajun Yang, Ascentage Pharma CEO, joins 'Closing Bell Overtime' to talk today's IPO. Marilyn Manson won’t face sexual assault, domestic violence charges in LA
Ascentage Pharma’s US Shares Climb After $126 Million IPO
Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s US trading debut, after pricing its $126.4 million initial public offering at a discount to its Asian stock.
Rockville's Ascentage Pharma seeks to raise $134M in U.S. IPO
A global biopharma with a U.S. headquarters in Montgomery County is gearing up to go public on a U.S. exchange.
Ascentage Pharma IPO opens flat
IPO began trading Friday on the NASDAQ. Shares opened at $17.25 per ADS, in line with the initial public offering (IPO) price of $17.25. The pharmaceutical company, already listed on the Main Board of the Stock Exchange of Hong Kong Limited under the code 6855.
Ascentage Pharma raises $126M via U.S. IPO (update)
Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.
Chinese Biotech Ascentage Aims For $134M IPO
Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia and for certain types of chronic myeloid leukemia.
Takeda-backed Ascentage Pharma targets $1.8 bln valuation in US IPO
Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.
Ascentage Pharma raises $126m in first biotech IPO of 2025
The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood cancer.
Ascentage prices first biotech IPO of 2025, raising $126M
The China-based drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.
Takeda-backed Ascentage Pharma aims to raise $126 million in US IPO
Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.
FierceBiotech1h
Metsera eyes $289M IPO to fund phase 3 weight loss trial
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...
Ascentage Pharma ADSs to Begin Trading on Nasdaq
Ascentage Pharma Group said its American depositary shares were slated to begin trading on the Nasdaq Global Market on Friday, with its initial public offering priced at $17.25 per ADS.